Licensed Professional Counselor Yvette Bunting-Watts puts it simply: “No one enjoys feeling the lack of joy.” Bunting-Watts, knows the topic of mental health well, as she is the founder and CEO of ...

Myers Squibb Company, Johnson & Johnson, Bausch Health Companies Inc, AbbVie Inc. Read 's Market Analysis on Investing.com ...

Johnson & Johnson’s other depression drug Spravato (esketamine), in January, received FDA approval as the only monotherapy for adults living with major depressive disorder who have had an ...

POCATELLO — An Idaho State University alumnus has returned to Pocatello to address the high demand for mental health services in the area by opening a new psychiatric clinic in town. EJ Weston ...

Streaming ads are an inevitability. They interrupt our Netflix binges, cut into Hulu dramas, and disrupt our Spotify playlists. They also support the content-creation economy on YouTube.

Neuronetics is focusing on expanding its Better Me Provider program and the SPRAVATO treatment at Greenbrook locations as part of its growth strategy. This article was generated with the support ...

Neuronetics reported a revenue increase of 11% year-over-year. The company shipped 46 NeuroStar systems, contributing $3.8 million in revenue. Neuronetics completed the acquisition of Greenbrook TMS, ...

And in for Spravato, we have 63 of our clinics that are ... Or is there a max number of ads you're keeping in mind. Thanks. Our goal is if they all make it that we would add them all into the ...

In contrast to generic ketamine, Spravato, an intranasal version of ketamine (esketamine), is FDA-approved and therefore is highly regulated. I’m amazed at the differences between the rollout of ...

Ketamine has gained attention for its depression treatment potential, particularly with the FDA approval of Spravato nasal spray. Market growth is driven by rising mental health issues ...

Ketamine has gained attention for its depression treatment potential, particularly with the FDA approval of Spravato nasal spray.

Ketamine has gained attention for its depression treatment potential, particularly with the FDA approval of Spravato nasal spray. Market growth is driven by rising mental health issues ...